Skip to main content
. Author manuscript; available in PMC: 2014 Mar 9.
Published in final edited form as: Nat Rev Microbiol. 2008 Jul;6(7):529–540. doi: 10.1038/nrmicro1927

Figure 5. Strategies to improve oncolytic virus efficacy.

Figure 5

a | Shielding the virus against antibodies. Pre-existing neutralizing antibodies in humans can interfere with efficacy. Changing virus serotypes and coating particles with shielding polymers can address the neutralizing-antibody problem. b | Transient immunosuppression of the host. Infected cells can be attacked by macrophages, T cells and natural killer cells. Transient immunosuppression interferes with the activation and ability of these cells to recognize and/or kill infected cells and restrict oncolytic efficacy.